Skip to main content
Top
Published in: Arthritis Research & Therapy 3/2004

01-09-2004 | Oral presentation

Menopause and hormone replacement therapy: effects on the immune system, arthritis and bone

Authors: H Carlsten, H Forsblad D'Elia, M Erlandsson, U Islander

Published in: Arthritis Research & Therapy | Special Issue 3/2004

Login to get access

Excerpt

Menopause is, among other things, associated with increased risk of bone loss and development of rheumatoid arthritis (RA). Numerous postmenopausal women in the Western world have replaced the endogenous estrogen by treatment with hormone replacement therapy (HRT) (i.e. estrogen + progestin) or estrogen replacement therapy (ERT) (i.e. estrogen alone). Until recently HRT was also regarded as preventive of cardiovascular disease, and possibly even dementia. However, recent findings in large placebo-controlled studies of long-term HRT and ERT in healthy postmenopausal women demonstrated an increased risk of coronary events, stroke, breast cancer and pulmonary embolism among the HRT-treated women. Consequently, today HRT is only recommended for 3–6 months in women with severe menopausal symptoms. …
Literature
1.
go back to reference Forsblad d'Elia H, Larsen A, Mattson L-Å, Waltbrand E, Kvist G, Mellström D, Saxne T, Ohlsson C, Nordborg E, Carlsten H: The impact of hormone replacement therapy on disease progression and bone mineral density in rheumatoid arthritis. J Rheumatol. 2003, 30: 1456-1463. Forsblad d'Elia H, Larsen A, Mattson L-Å, Waltbrand E, Kvist G, Mellström D, Saxne T, Ohlsson C, Nordborg E, Carlsten H: The impact of hormone replacement therapy on disease progression and bone mineral density in rheumatoid arthritis. J Rheumatol. 2003, 30: 1456-1463.
2.
go back to reference Erlandsson MC, Jonsson CA, Islander U, Ohlsson C, Carlsten H: Oestrogen receptor specificity in oestradiol-mediated effects on B lymphopoiesis and immunoglobulin production in male mice. Immunology. 2003, 108: 346-351. 10.1046/j.1365-2567.2003.01599.x.CrossRefPubMedCentralPubMed Erlandsson MC, Jonsson CA, Islander U, Ohlsson C, Carlsten H: Oestrogen receptor specificity in oestradiol-mediated effects on B lymphopoiesis and immunoglobulin production in male mice. Immunology. 2003, 108: 346-351. 10.1046/j.1365-2567.2003.01599.x.CrossRefPubMedCentralPubMed
3.
go back to reference Islander U, Erlandsson M, Hasseus B, Jonsson CA, Ohlsson C, Gustafssson J-Å, Dahlgren U, Carlsten H: Influence of oestrogen receptor α and β on the immune system in aged female mice. Immunology. 2003, 110: 149-157. 10.1046/j.1365-2567.2003.01704.x.CrossRefPubMedCentralPubMed Islander U, Erlandsson M, Hasseus B, Jonsson CA, Ohlsson C, Gustafssson J-Å, Dahlgren U, Carlsten H: Influence of oestrogen receptor α and β on the immune system in aged female mice. Immunology. 2003, 110: 149-157. 10.1046/j.1365-2567.2003.01704.x.CrossRefPubMedCentralPubMed
4.
go back to reference Erlandsson MC, Jonsson CA, Lindberg MK, Ohlsson C, Carlsten H: Raloxifene- and estradiol-mediated effects on uterus, bone and B lymphocytes in mice. J Endocrinol. 2002, 175: 319-327. 10.1677/joe.0.1750319.CrossRefPubMed Erlandsson MC, Jonsson CA, Lindberg MK, Ohlsson C, Carlsten H: Raloxifene- and estradiol-mediated effects on uterus, bone and B lymphocytes in mice. J Endocrinol. 2002, 175: 319-327. 10.1677/joe.0.1750319.CrossRefPubMed
5.
go back to reference Movérare S, Dahllund J, Andersson N, Islander U, Carlsten H, Gustafsson J-Å, Nilsson S, Ohlsson C: Estren is a selective estrogen receptor modulator with transcriptional activity. Mol Pharmacol. 2003, 64: 1428-1433. 10.1124/mol.64.6.1428.CrossRefPubMed Movérare S, Dahllund J, Andersson N, Islander U, Carlsten H, Gustafsson J-Å, Nilsson S, Ohlsson C: Estren is a selective estrogen receptor modulator with transcriptional activity. Mol Pharmacol. 2003, 64: 1428-1433. 10.1124/mol.64.6.1428.CrossRefPubMed
Metadata
Title
Menopause and hormone replacement therapy: effects on the immune system, arthritis and bone
Authors
H Carlsten
H Forsblad D'Elia
M Erlandsson
U Islander
Publication date
01-09-2004
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue Special Issue 3/2004
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar1371

Other articles of this Special Issue 3/2004

Arthritis Research & Therapy 3/2004 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine